Vontobel Holding Ltd. Decreases Stake in Solventum Corporation $SOLV

Vontobel Holding Ltd. reduced its stake in Solventum Corporation (NYSE:SOLV) by 34.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,537 shares of the company’s stock after selling 1,820 shares during the quarter. Vontobel Holding Ltd.’s holdings in Solventum were worth $268,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Independent Franchise Partners LLP grew its holdings in shares of Solventum by 263.1% during the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after buying an additional 4,217,570 shares during the last quarter. Boston Partners raised its stake in shares of Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock worth $255,554,000 after purchasing an additional 1,691,565 shares during the last quarter. Nuveen LLC purchased a new position in shares of Solventum in the first quarter worth about $35,375,000. Diamond Hill Capital Management Inc. raised its stake in shares of Solventum by 139.6% in the first quarter. Diamond Hill Capital Management Inc. now owns 577,173 shares of the company’s stock worth $43,888,000 after purchasing an additional 336,282 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Solventum in the first quarter worth about $23,572,000.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target on the stock. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. Piper Sandler restated an “overweight” rating and set a $94.00 target price (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Wall Street Zen downgraded shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Solventum in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $84.89.

Solventum Price Performance

Shares of NYSE SOLV opened at $71.67 on Thursday. The firm has a market cap of $12.43 billion, a PE ratio of 33.18, a PEG ratio of 2.91 and a beta of 0.50. The firm has a fifty day moving average of $72.67 and a 200 day moving average of $72.04. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter last year, the business earned $1.56 earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.